17-alpha-hydroxyprogesterone has been researched along with Preterm Birth in 44 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (15.91) | 29.6817 |
| 2010's | 21 (47.73) | 24.3611 |
| 2020's | 16 (36.36) | 2.80 |
| Authors | Studies |
|---|---|
| Finneran, MM; Frey, HA; Hade, EM; Iams, JD; Landon, MB; Lynch, CD; Waickman, C | 1 |
| Abdulrahman Hadi, BA; Ismael, WA; Nori, W | 1 |
| Backley, S; Berghella, V; Boelig, RC; Frey, H; Gimovsky, AC; Schoen, CN; Springel, E | 1 |
| Biron-Shental, T; Cohen, G; Miller, N; Moran, R; Ovadia, M; Schreiber, H; Shavit, M; Shechter-Maor, G; Weitzner, O; Yagur, Y | 1 |
| Beam, AL; Hakim, JB; Hart, JM; Wylie, BJ | 1 |
| Smith, MM; Swamy, GK; Truong, T; Weber, JM; Wheeler, SM | 1 |
| Cole, SR; Conner, MG; Freeman, BL; Kasaro, MP; Mabula-Bwalya, CM; Price, JT; Sebastião, YV; Stringer, EM; Stringer, JSA; Vwalika, B | 1 |
| Alshabi, A; Bastian, JR; Caritis, S; Chaphekar, N; Shaik, IH; Vasudevan, V; Venkataramanan, R; Zhao, W | 1 |
| Caritis, SN; Chauhan, SP; Clark, S; Costantine, MM; Kiley, JW; Metz, TD; Stika, CS; Venkataramanan, R | 1 |
| Affan, M; Ilyas, E | 1 |
| Norman, JE | 1 |
| Caritis, SN; Combs, CA; Lemon, L; Megli, C; Venkataramanan, R | 1 |
| Babbar, S; Edwards, AM; Forinash, AB; Lowry, SA; Mikovich, S | 1 |
| Hesson, AM; Langen, ES; Pitts, DS | 1 |
| Abdalla, A; Dotters-Katz, SK; Hynes, JS; Manuck, TA; Schwartz, AR | 1 |
| Elovitz, MA; Levine, LD; Purisch, SE; Turitz, AL | 1 |
| Blackwell, SC; Caritis, SN; Esplin, MS; Grobman, WA; Iams, JD; Leveno, KJ; Mercer, BM; Reddy, UM; Rouse, DJ; Saade, GR; Sorokin, Y; Thom, EA; Thorp, JM; Tita, ATN; Tolosa, JE; Vandorsten, JP; Wapner, RJ | 1 |
| Leveno, KJ; McIntire, DD; Nelson, DB | 1 |
| Antsaklis, A; Bellos, I; Daskalakis, G; Hatziagelaki, E; Loutradis, D; Pergialiotis, V | 1 |
| Fox, N; Klauser, CK; Rebarber, A; Roman, AS; Saltzman, D | 1 |
| Cincotta, R; Crowther, CA; Dodd, JM; Flenady, V; Jones, L | 1 |
| Chakraborty, P; Ducharme, R; Hawken, S; Little, J; Potter, BK; Thébaud, B; Wilson, K | 1 |
| Cruz Ortiz, SG; Llorens, A; Pereira, OM; Rosa, ER | 1 |
| Audibert, F; Fuchs, F; Senat, MV | 1 |
| Ananth, CV; Brubaker, SG; Drassinower, D; Pessel, C; Vani, K; Vink, J; Zork, N | 1 |
| Bastek, JA; Elovitz, MA; Levine, LD; Purisch, SE; Turitz, AL | 1 |
| Devoe, LD | 1 |
| Bernardi, RD; Coeli, FB; de-Mello, MP; Justo, GZ; Lemos-Marini, SH; Maturana, VG; Silva, MD; Soardi, FC | 1 |
| Ramin, SM; Vidaeff, AC | 1 |
| Desch, CN; Istwan, NB; Joy, S; Rhea, DJ; Stanziano, G | 1 |
| Hu, YL; Yang, HX; Zhou, YH | 1 |
| Iams, JD | 1 |
| Balducci, J; Garfield, RE; Kuon, RJ; Maner, WL; Maul, H; Shi, SQ; Sohn, C | 1 |
| de la Torre, L; Desch, C; González-Quintero, VH; Istwan, NB; Rhea, DJ; Tudela, CM; Vazquez-Vera, E | 1 |
| Combs, CA; Das, A; Garite, T; Maurel, K; Porto, M | 1 |
| Briery, CM; Chauhan, SP; Klauser, CK; Magann, EF; Martin, RW; Morrison, JC; Veillon, EW | 1 |
| Esplin, MS; Gibson, J; Henry, E; Jackson, GM; Manuck, TA; Porter, TF; Varner, MW | 1 |
| Caritis, SN; Carpenter, M; Harper, M; Iams, JD; Lo, J; Malone, FD; Mercer, BM; Peaceman, AM; Ramin, SM; Rouse, DJ; Sciscione, A; Simhan, HN; Sorokin, Y; Spong, CY; Thorp, JM; Varner, MW; Zhao, Y | 1 |
| Chaiworapongsa, T; Conde-Agudelo, A; Hassan, SS; Miranda, J; Romero, R; Yeo, L | 1 |
| Meis, PJ | 1 |
| Caritis, SN; Carpenter, M; Conway, D; Dombrowski, MP; Gabbe, S; Hauth, JC; Iams, JD; Leveno, KJ; Meis, PJ; Mercer, B; Miodovnik, M; Moawad, AH; O'Sullivan, MJ; Peaceman, AM; Ramin, SM; Sibai, B; Spong, CY; Thom, EA; Thorp, JM; Varner, MW; Wapner, RJ | 1 |
| Cincotta, R; Crowther, CA; Dodd, JM; Flenady, V | 1 |
| Cleary-Goldman, J; Istwan, NB; Rebarber, A; Rhea, DJ; Russo-Stieglitz, K; Saltzman, DH; Stanziano, GJ | 1 |
11 review(s) available for 17-alpha-hydroxyprogesterone and Preterm Birth
| Article | Year |
|---|---|
The efficiency of 17a hydroxyprogesterone in the prevention of preterm labour irrespective of administration route: Systematic review metanalysis.
Topics: 17-alpha-Hydroxyprogesterone; Female; Humans; Infant, Newborn; Iraq; Pregnancy; Premature Birth; Progesterone | 2021 |
Racial and ethnic representation in 17-hydroxyprogesterone caproate preterm birth prevention studies: a systematic review.
Topics: 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-Hydroxyprogesterone; Caproates; Ethnicity; Female; Humans; Infant, Newborn; Premature Birth | 2022 |
Progesterone and preterm birth.
Topics: 17-alpha-Hydroxyprogesterone; Administration, Intravaginal; Adult; Cervical Length Measurement; Cost-Benefit Analysis; Female; Humans; Infant, Newborn; Injections, Intramuscular; Mass Screening; Pregnancy; Premature Birth; Progesterone; Progestins | 2020 |
Evaluating Progestogens for Preventing Preterm birth International Collaborative (EPPPIC): meta-analysis of individual participant data from randomised controlled trials.
Topics: 17-alpha-Hydroxyprogesterone; Administration, Intravaginal; Decision Making, Shared; Female; Humans; Infant, Newborn; Injections, Intramuscular; Pregnancy; Pregnancy Outcome; Pregnancy, High-Risk; Premature Birth; Progesterone; Randomized Controlled Trials as Topic; Risk Assessment | 2021 |
Progestogens for the prevention of preterm birth and risk of developing gestational diabetes mellitus: a meta-analysis.
Topics: 17-alpha-Hydroxyprogesterone; Administration, Intravaginal; Diabetes, Gestational; Female; Humans; Pregnancy; Premature Birth; Progesterone; Progestins | 2019 |
Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth.
Topics: 17-alpha-Hydroxyprogesterone; Female; Humans; Pregnancy; Pregnancy, High-Risk; Premature Birth; Prenatal Care; Progesterone; Randomized Controlled Trials as Topic | 2013 |
[Progesterone and preterm delivery: back to the future?].
Topics: 17-alpha-Hydroxyprogesterone; Administration, Intravaginal; Female; France; Humans; Pregnancy; Premature Birth; Progesterone; Randomized Controlled Trials as Topic; Uterine Cervical Incompetence | 2014 |
Management strategies for the prevention of preterm birth. Part I: Update on progesterone supplementation.
Topics: 17-alpha-Hydroxyprogesterone; Cervix Uteri; Clinical Trials as Topic; Female; Humans; Pregnancy; Pregnancy, High-Risk; Premature Birth; Progesterone; Progestins; Ultrasonography | 2009 |
A blueprint for the prevention of preterm birth: vaginal progesterone in women with a short cervix.
Topics: 17-alpha-Hydroxyprogesterone; Administration, Intravaginal; Cervix Uteri; Female; Humans; Pregnancy; Pregnancy, High-Risk; Premature Birth; Risk; Ultrasonography | 2013 |
17 hydroxyprogesterone for the prevention of preterm delivery.
Topics: 17-alpha-Hydroxyprogesterone; Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gestational Age; Humans; Obstetric Labor, Premature; Pregnancy; Pregnancy Outcome; Pregnancy, High-Risk; Pregnancy, Multiple; Premature Birth; Prenatal Care; Randomized Controlled Trials as Topic; Reference Values; Risk Assessment; Treatment Outcome | 2005 |
Prenatal administration of progesterone for preventing preterm birth.
Topics: 17-alpha-Hydroxyprogesterone; Female; Humans; Pregnancy; Premature Birth; Progesterone; Randomized Controlled Trials as Topic | 2006 |
7 trial(s) available for 17-alpha-hydroxyprogesterone and Preterm Birth
| Article | Year |
|---|---|
Vaginal progesterone vs intramuscular 17-hydroxyprogesterone caproate for prevention of recurrent preterm birth: a randomized controlled trial.
Topics: 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-Hydroxyprogesterone; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Pregnancy; Premature Birth; Progesterone; Progestins | 2022 |
Effect of weekly 17-hydroxyprogesterone caproate on small for gestational age among pregnant women with HIV in Zambia.
Topics: 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-Hydroxyprogesterone; Female; Gestational Age; HIV Infections; Humans; Hydroxyprogesterones; Infant; Pregnancy; Pregnant Women; Premature Birth; Zambia | 2022 |
Relationship between plasma concentration of 17-hydroxyprogesterone caproate and gestational age at preterm delivery.
Topics: 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-Hydroxyprogesterone; Female; Gestational Age; Humans; Hydroxyprogesterones; Infant, Newborn; Premature Birth | 2023 |
Adherence rates and outcomes for 17-hydroxyprogesterone caproate use in women with a previous history of preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-Hydroxyprogesterone; Adult; Female; Humans; Hydroxyprogesterones; Infant; Infant, Newborn; Pregnancy; Premature Birth; Retrospective Studies; United States | 2020 |
Failure of 17-hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double-blind, randomized clinical trial.
Topics: 17-alpha-Hydroxyprogesterone; Abortion, Spontaneous; Adult; Double-Blind Method; Female; Fetal Death; Gestational Age; Humans; Infant, Newborn; Infant, Newborn, Diseases; Pregnancy; Pregnancy Complications; Pregnancy, High-Risk; Pregnancy, Multiple; Premature Birth; Triplets | 2010 |
Women with preterm premature rupture of the membranes do not benefit from weekly progesterone.
Topics: 17-alpha-Hydroxyprogesterone; Adult; Algorithms; Drug Administration Schedule; Female; Fetal Membranes, Premature Rupture; Fetal Mortality; Gestational Age; Humans; Labor Stage, First; Mississippi; Pregnancy; Premature Birth; Statistics, Nonparametric; Young Adult | 2011 |
Relationship between 17-hydroxyprogesterone caproate concentrations and gestational age at delivery in twin gestation.
Topics: 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-Hydroxyprogesterone; Adult; Biomarkers; C-Reactive Protein; Corticotropin-Releasing Hormone; Female; Gestational Age; Humans; Hydroxyprogesterones; Pregnancy; Pregnancy, Twin; Premature Birth; Progesterone; Progestins; Treatment Outcome | 2012 |
26 other study(ies) available for 17-alpha-hydroxyprogesterone and Preterm Birth
| Article | Year |
|---|---|
A Comparison of Vaginal and Intramuscular Progesterone for the Prevention of Recurrent Preterm Birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-Hydroxyprogesterone; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Pregnancy; Premature Birth; Progesterone; Retrospective Studies | 2023 |
Can 17 hydroxyprogesterone caproate (17P) decrease preterm deliveries in patients with a history of PMC or pPROM?
Topics: 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-Hydroxyprogesterone; Female; Fetal Membranes, Premature Rupture; Humans; Infant, Newborn; Obstetric Labor, Premature; Pregnancy; Premature Birth; Retrospective Studies | 2022 |
Regional differences in utilization of 17α-hydroxyprogesterone caproate (17-OHP).
Topics: 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-Hydroxyprogesterone; Cohort Studies; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Pregnancy; Premature Birth; Retrospective Studies | 2022 |
Effect of formulation and route of administration on the distribution of 17-hydroxyprogesterone caproate in rats.
Topics: 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-Hydroxyprogesterone; Animals; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Premature Birth; Rats; Rats, Sprague-Dawley | 2023 |
Discontinuation Of Long-Established Hydroxyprogesterone Caproate; Call For Awareness And Drug-Substitutes: A Letter To The Editor.
Topics: 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-Hydroxyprogesterone; Female; Humans; Premature Birth | 2023 |
Recurrent Preterm Birth Reduction by 17-Hydroxyprogesterone Caproate in Dichorionic/Diamniotic Twin Gestation.
Topics: 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-Hydroxyprogesterone; Female; Humans; Infant, Newborn; Pregnancy; Pregnancy, Twin; Premature Birth; Prospective Studies; Randomized Controlled Trials as Topic | 2022 |
Delivering equity: preterm birth by socioeconomic class before and after coverage of 17-hydroxyprogesterone caproate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-Hydroxyprogesterone; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Premature Birth; Retrospective Studies; Socioeconomic Factors; United States | 2022 |
17-hydroxyprogesterone caproate for women with congenital uterine anomalies: does it impact the risk of recurrent preterm birth?
Topics: 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-Hydroxyprogesterone; Female; Humans; Infant, Newborn; Pregnancy; Premature Birth; Urogenital Abnormalities; Uterus | 2021 |
The Effect of Prior Term Birth on Risk of Recurrent Spontaneous Preterm Birth.
Topics: 17-alpha-Hydroxyprogesterone; Adult; Birth Order; Female; Gestational Age; Humans; Infant, Newborn; Logistic Models; Multivariate Analysis; Pennsylvania; Pregnancy; Pregnancy Outcome; Premature Birth; Recurrence; Retrospective Studies; Risk Factors; Term Birth; Young Adult | 2018 |
Cervical funneling or intra-amniotic debris and preterm birth in nulliparous women with midtrimester cervical length less than 30 mm.
Topics: 17-alpha-Hydroxyprogesterone; Adult; Amniotic Fluid; Cervical Length Measurement; Cervix Uteri; Cohort Studies; Female; Humans; Maternal Age; Pregnancy; Pregnancy Trimester, Second; Premature Birth; Randomized Controlled Trials as Topic; Ultrasonography, Prenatal; Young Adult | 2018 |
Defining 17OHP-C responsiveness.
Topics: 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-Hydroxyprogesterone; Female; Humans; Pregnancy; Premature Birth | 2019 |
A national survey examining obstetrician perspectives on use of 17-alpha hydroxyprogesterone caproate post-US FDA approval.
Topics: 17-alpha-Hydroxyprogesterone; Attitude of Health Personnel; Data Collection; Drug Approval; Female; Humans; Male; Obstetrics; Practice Patterns, Physicians'; Premature Birth; United States; United States Food and Drug Administration; Workforce | 2013 |
Metabolomics of prematurity: analysis of patterns of amino acids, enzymes, and endocrine markers by categories of gestational age.
Topics: 17-alpha-Hydroxyprogesterone; Amino Acids; Arginine; Birth Weight; Cohort Studies; Endocrine System; Enzymes; Female; Gestational Age; Humans; Infant, Newborn; Infant, Premature; Leucine; Male; Metabolome; Neonatal Screening; Ontario; Premature Birth; Thyrotropin-Releasing Hormone; Time Factors; Valine | 2014 |
Pregnancy and neonatal outcomes of women receiving compounded 17-alpha hydroxyprogesterone at San Juan City hospital.
Topics: 17-alpha-Hydroxyprogesterone; Adult; Birth Weight; Drug Evaluation; Female; Gestational Age; Home Care Services, Hospital-Based; Humans; Infant, Newborn; Infant, Premature; Injections, Intramuscular; Male; Obstetric Labor, Premature; Pregnancy; Pregnancy Outcome; Premature Birth; Puerto Rico; Recurrence; Stillbirth; Tocolytic Agents; Urban Population | 2013 |
Effect of cervical cerclage on rate of cervical shortening.
Topics: 17-alpha-Hydroxyprogesterone; Adult; Cerclage, Cervical; Cervical Length Measurement; Cervix Uteri; Female; Humans; Obstetric Labor, Premature; Pregnancy; Pregnancy Outcome; Pregnancy, High-Risk; Premature Birth; Progesterone; Retrospective Studies; Uterine Cervical Incompetence; Vagina | 2015 |
Patient characteristics associated with 17-alpha hydroxyprogesterone caproate use among a high-risk cohort.
Topics: 17-alpha-Hydroxyprogesterone; Adult; Cerclage, Cervical; Cross-Sectional Studies; Female; Fetal Death; Humans; Patient Acceptance of Health Care; Pennsylvania; Pregnancy; Pregnancy, High-Risk; Premature Birth; Progestins; Recurrence | 2016 |
Parenteral therapy in today's obstetric practice.
Topics: 17-alpha-Hydroxyprogesterone; Anticoagulants; Female; Heparin, Low-Molecular-Weight; Humans; Pregnancy; Pregnancy Complications, Hematologic; Premature Birth; Tocolytic Agents; Venous Thromboembolism | 2008 |
Heterozygosis for CYP21A2 mutation considered as 21-hydroxylase deficiency in neonatal screening.
Topics: 17-alpha-Hydroxyprogesterone; Adrenal Hyperplasia, Congenital; False Positive Reactions; Female; Heterozygote; Humans; Infant, Newborn; Male; Mutation; Neonatal Screening; Pregnancy; Premature Birth; Steroid 21-Hydroxylase | 2008 |
The risk for preterm labor in women receiving 17 alpha-hydroxyprogesterone caproate prophylaxis for preterm birth prevention.
Topics: 17-alpha-Hydroxyprogesterone; Adult; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fetal Monitoring; Follow-Up Studies; Gestational Age; Humans; Infant, Newborn; Obstetric Labor, Premature; Pregnancy; Pregnancy Outcome; Pregnancy, High-Risk; Premature Birth; Probability; Recurrence; Retrospective Studies; Risk Assessment | 2010 |
[Pay more attention to prevention and treatment of complications during pregnancy].
Topics: 17-alpha-Hydroxyprogesterone; Anti-Bacterial Agents; Female; Hepatitis B; Humans; Immunoglobulins; Infectious Disease Transmission, Vertical; Obstetric Labor Complications; Pregnancy; Pregnancy Complications; Premature Birth; Progesterone | 2010 |
Was the preterm birth rate in the placebo group too high in the Meis MFMU Network trial of 17-OHPC?
Topics: 17-alpha-Hydroxyprogesterone; Castor Oil; Female; Humans; Oxytocin; Pregnancy; Pregnancy Trimester, Third; Premature Birth; Randomized Controlled Trials as Topic; Recurrence; Risk Assessment; Risk Factors; Uterine Contraction | 2010 |
Pharmacologic actions of progestins to inhibit cervical ripening and prevent delivery depend on their properties, the route of administration, and the vehicle.
Topics: 17-alpha-Hydroxyprogesterone; Animals; Cervical Ripening; Female; Fish Oils; Lipids; Pregnancy; Premature Birth; Progesterone; Progestins; Promegestone; Rats; Rats, Sprague-Dawley; Sesame Oil; Vaginal Creams, Foams, and Jellies | 2010 |
Impact of prior gestational age at preterm delivery on effectiveness of 17-alpha-hydroxyprogesterone caproate in practice.
Topics: 17-alpha-Hydroxyprogesterone; Adult; Female; Gestational Age; Humans; Pregnancy; Pregnancy, High-Risk; Premature Birth; Retrospective Studies; Secondary Prevention | 2010 |
Pregnancy outcomes in a recurrent preterm birth prevention clinic.
Topics: 17-alpha-Hydroxyprogesterone; Adult; Cervical Length Measurement; Clinical Protocols; Cohort Studies; Female; Gynecological Examination; Humans; Male; Nifedipine; Outpatient Clinics, Hospital; Pregnancy; Pregnancy Outcome; Premature Birth; Retrospective Studies; Secondary Prevention; Tocolytic Agents; Urinalysis; Utah | 2011 |
Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery.
Topics: 17-alpha-Hydroxyprogesterone; Female; Gestational Age; Humans; Logistic Models; Pregnancy; Premature Birth; Proportional Hazards Models; Recurrence | 2005 |
Increased incidence of gestational diabetes in women receiving prophylactic 17alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adult; Caproates; Diabetes, Gestational; Female; Humans; Incidence; Injections, Intramuscular; Pregnancy; Premature Birth; Recurrence; Tocolytic Agents | 2007 |